Registration Number
0224U000699,
(0117U005123)
, R & D reports
Title
Esophagogastroduodenal peptic (acid-related) and HP-associated diseases with comorbidity: the ways of improvement in diagnostics, treatment and prevention by means of multichannel intraluminal impedance-pH-monitoring.
popup.stage_title
Езофагогастродуоденальна пептична (кислотозалежна) та H.p.-асоційована патологія з коморбідним перебігом: можливості езофагогастро-імпеданс-рН-моніторингу в покращенні діагностики, лікування та профілактики.
Head
Palii Iryna Н., Доктор медичних наук
Registration Date
10-01-2024
Organization
Vinnytsia National Pirogov Memorial Medical University
popup.description1
popup.description2
The solution to the urgent task of increasing the effectiveness of anti-Helicobacter pharmacotherapy in the treatment of acid-dependent gastroesophageal diseases is provided based on the study of the results of breathing tests with 13C-labeled urea, analysis of indicators of express gastro-pH monitoring, multi-hour (daily) esophago-gastro-pH monitoring in combination with multichannel intraluminal impedance monitoring and the use of modern GerdQ and GSRS questionnaires. the study was performed on 2094 adult patients aged 17 to 85 years. A general trend towards a decrease in Helicobacter pylori infection in the Vinnytsia population to 33.3% in 2019 was revealed. The results of express gastro-pH monitoring, which was performed before the start of the course of eradication therapy, can also be a predictor of successful eradication, in particular: min pH >2.2 (ROC AUC=0.62). Predictors of successful eradication can be indicators of express gastro-pH monitoring, which is performed on the 5-7th day of therapy with a median pH >4.4 (ROC AUC= 0.71). Maintenance of intragastric pH ≥5.0 for 14.9±1.9 hours. and the level of intragastric pH≥6.0 for 10.8±1.7 hours. per day is sufficient for successful eradication of Helicobacter pylori. The sensitivity and specificity of the GerdQ questionnaire in the diagnosis of gastroesophageal reflux disease in outpatient settings is 78.6% and 92.9%, respectively. (ROC AUC=0.95). In patients with this disease in combination with arterial hypertension, in comparison with patients without this comorbidity, a decrease in the aggressiveness of acid refluxate was found according to three-hour esophageal-gastro-pH-monitoring. The use of valsartan in patients with this common comorbidity, in contrast to the effects of taking lisinopril, bisoprolol, and amlodipine, led to an increase in the exposure of gastric acid contents to the esophagus, due to an increase in the number of episodes of acid reflux, a decrease in the minimum pH in the esophagus
Product Description
popup.authors
Zaika Serhiі Volodymyrovych
Kondratyuk Natalia Mykolaivna
Ksenchyn Oleh Oleksandrovych
Melashchenko Sergii Hrygorovych
Pivtorak Natalia Anatoliivna
Paliy Iryna Hordiivna
Chernova Inna Vjacheslavivna
popup.nrat_date
2024-01-10
